JP2005511594A - 肥満の治療における、もしくは摂食量の減少のためのスルホンアミド誘導体の使用 - Google Patents

肥満の治療における、もしくは摂食量の減少のためのスルホンアミド誘導体の使用 Download PDF

Info

Publication number
JP2005511594A
JP2005511594A JP2003541838A JP2003541838A JP2005511594A JP 2005511594 A JP2005511594 A JP 2005511594A JP 2003541838 A JP2003541838 A JP 2003541838A JP 2003541838 A JP2003541838 A JP 2003541838A JP 2005511594 A JP2005511594 A JP 2005511594A
Authority
JP
Japan
Prior art keywords
alkyl
group
compound
formula
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003541838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511594A5 (https=
Inventor
パトリツィア・カルディロラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0103767A external-priority patent/SE0103767D0/xx
Application filed by Biovitrum AB filed Critical Biovitrum AB
Publication of JP2005511594A publication Critical patent/JP2005511594A/ja
Publication of JP2005511594A5 publication Critical patent/JP2005511594A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Cosmetics (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2003541838A 2001-11-09 2002-11-06 肥満の治療における、もしくは摂食量の減少のためのスルホンアミド誘導体の使用 Pending JP2005511594A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0103767A SE0103767D0 (sv) 2001-11-09 2001-11-09 New use
US35689002P 2002-02-13 2002-02-13
PCT/SE2002/002019 WO2003039547A1 (en) 2001-11-09 2002-11-06 Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake

Publications (2)

Publication Number Publication Date
JP2005511594A true JP2005511594A (ja) 2005-04-28
JP2005511594A5 JP2005511594A5 (https=) 2006-01-05

Family

ID=26655592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003541838A Pending JP2005511594A (ja) 2001-11-09 2002-11-06 肥満の治療における、もしくは摂食量の減少のためのスルホンアミド誘導体の使用

Country Status (6)

Country Link
US (1) US20030166663A1 (https=)
EP (1) EP1450806B1 (https=)
JP (1) JP2005511594A (https=)
AT (1) ATE429916T1 (https=)
DE (1) DE60232173D1 (https=)
WO (1) WO2003039547A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7527376B2 (en) 2006-07-25 2009-05-05 Seiko Epson Corporation Method for designing spectacle lens, spectacle lens, and spectacles

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1897881A3 (en) * 2002-06-20 2009-03-18 Biovitrum AB (publ) Compounds useful for the treatment of obesity, type II diabetes and CNS disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2228268B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2228267B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
WO2006047302A1 (en) * 2004-10-21 2006-05-04 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
EP1910321A4 (en) * 2005-07-05 2010-09-01 Astrazeneca Ab NEW COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, INTERMEDIATE PRODUCTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6-MEDIATED ILLNESSES SUCH AS ALZHEIMER'S DISEASE, COGNITIVE ILLUSTRATIONS, SCHOISOPHRENIC ASSOCIATED COGNITIVE DISORDERS, OBESITAS AND PARKINSON DISEASE
JP2009500406A (ja) * 2005-07-05 2009-01-08 アストラゼネカ・アクチエボラーグ 新規化合物、その製造方法、中間体、医薬組成物、並びにアルツハイマー病、認知障害、統合失調症に伴う認識機能障害、肥満及びパーキンソン病のような５−ｈｔ６介在疾患の治療におけるそれらの使用
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
ES2664873T3 (es) 2011-03-01 2018-04-23 Synergy Pharmaceuticals Inc. Proceso de preparación de agonistas de guanilato ciclasa C
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE201403T1 (de) 1993-03-16 2001-06-15 Pfizer Naphtalinderivate
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
WO1999044609A1 (en) * 1998-03-03 1999-09-10 Merck & Co., Inc. FUSED PIPERIDINE SUBSTITUTED ARYLSULFONAMIDES AS β3-AGONISTS
TWI222450B (en) * 1999-07-28 2004-10-21 Upjohn Co Oxazinocarbazoles for the treatment of CNS diseases
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
US6399617B1 (en) * 2000-07-21 2002-06-04 Biovitrum Ab Use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7527376B2 (en) 2006-07-25 2009-05-05 Seiko Epson Corporation Method for designing spectacle lens, spectacle lens, and spectacles

Also Published As

Publication number Publication date
ATE429916T1 (de) 2009-05-15
DE60232173D1 (de) 2009-06-10
EP1450806A1 (en) 2004-09-01
EP1450806B1 (en) 2009-04-29
US20030166663A1 (en) 2003-09-04
WO2003039547A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
JP2005511594A (ja) 肥満の治療における、もしくは摂食量の減少のためのスルホンアミド誘導体の使用
KR100386229B1 (ko) 히드록시카르바졸화합물의평활근유주및증식의억제
AU2013358591B2 (en) Pyrimido [4,5-b]quinoline-4,5 (3H,10H)-diones as nonsense mutation suppressors
CN107405347B (zh) 用于治疗处理或美容处理过量体脂肪的nk-3受体拮抗剂
CA2149691A1 (en) Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia
PT92799B (pt) Utilizacao de um agonista parcial de glicina b, nomeadamente um composto amino-isoxazolidina, para a preparacao de um medicamento empregue como antipsicotico e processo para a preparacao de uma composicao farmaceutica contendo o referido agonista
KR100880806B1 (ko) 비만 치료용 세로토닌 길항제로서 아릴 술폰아미드
AU2001271225A1 (en) Aryl sulfonamides as serotonin antagonist for the treatment of obesity
KR100508626B1 (ko) 빈뇨·요실금 치료·예방제 및 트로폰 유도체
WO1999005146A1 (en) Hyponatremia remedies
JP7228529B2 (ja) １，４－ベンゾチアゼピン－１－オキシド誘導体の光学異性体を含む腎機能障害の改善薬
JP2007512267A (ja) 高尿酸血症の治療のためのペンタジエン酸誘導体の使用
CN119584967A (zh) 用甘氨酸转运抑制剂治疗肝性卟啉症的组合物和方法
JP2025541424A (ja) 線維症の処置のためのホスホグリセレートデヒドロゲナーゼ阻害剤
WO2021203779A1 (zh) 治疗肺动脉高压的化合物及其应用
JP2005002024A (ja) 止痒剤
JPH09221426A (ja) 神経細胞保護剤
TW201332997A (zh) Ｐ７５受體拮抗劑的新穎醫療用途
KR20040106345A (ko) 트로폴론 유도체를 사용한 경구투여용 빈뇨ㆍ요실금의치료제 또는 예방제 혹은 경구투여용 수면도입제
JPWO1999005146A1 (ja) 低ナトリウム血症治療薬
JPH10265385A (ja) 随意運動異常状態の改善剤
JP2000505060A (ja) パーキンソン病およびパーキンソン症候群を処置するための２―イミノベンゾチアゾリン類の使用
EA044055B1 (ru) Применение антагониста рецептора нейрокинина-3 (nk-3) для повышения уровней циркулирующего лептина у пациентов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051104

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090609

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100105